Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 5,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $25.18, for a total transaction of $125,900.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
NASDAQ DCPH opened at $25.89 on Friday. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $956.97 million, a price-to-earnings ratio of -8.66 and a beta of 3.38. Deciphera Pharmaceuticals Inc has a one year low of $18.55 and a one year high of $45.61.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, meeting analysts’ consensus estimates of ($0.65). On average, equities research analysts expect that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current year.
DCPH has been the subject of a number of research analyst reports. Guggenheim initiated coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 17th. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Tuesday, October 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a report on Wednesday, October 3rd. ValuEngine upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, B. Riley initiated coverage on shares of Deciphera Pharmaceuticals in a report on Monday, December 31st. They set a “buy” rating and a $34.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. Deciphera Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $42.67.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Further Reading: What are the components of an earnings report?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.